Clinical Trial Update: SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SHR-1701 in combination with liposomal irinotecan for second-line esophageal squamous cell carcinoma after immunotherapy; status is not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Irinotecan liposome (liposomal irinotecan)
• SHR-1701

Snippet

Sponsor: Zhigang Li | Conditions: ESCC | Phase 2 | Status: NOT_YET_RECRUITING